Drug Type Peptide Conjugate Radionuclide, Diagnostic radiopharmaceuticals |
Synonyms 68Ga-satoreotide, 68Ga-satoreotide trizoxetan, Satoreotide trizoxetan + [4] |
Target |
Mechanism SSTR2 antagonists(Somatostatin receptor 2 antagonists), PET imaging(Positron-emission tomography enhancers) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Molecular FormulaC73H95ClN18O21S2 |
InChIKeyMDDXVKPIPNUPBG-FDKGEFSASA-N |
CAS Registry1638746-88-9 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Small Cell Lung Cancer | Phase 2 | US | 14 May 2019 | |
Small Cell Lung Cancer | Phase 2 | AT | 14 May 2019 | |
Small Cell Lung Cancer | Phase 2 | BE | 14 May 2019 | |
Small Cell Lung Cancer | Phase 2 | FR | 14 May 2019 | |
Small Cell Lung Cancer | Phase 2 | DE | 14 May 2019 | |
Small Cell Lung Cancer | Phase 2 | CH | 14 May 2019 | |
Small Cell Lung Cancer | Phase 2 | GB | 14 May 2019 | |
Breast Cancer | Phase 2 | AT | 22 Oct 2018 | |
Gastro-Enteropancreatic Neuroendocrine Tumor | Phase 2 | US | 26 Sep 2017 | |
Gastro-Enteropancreatic Neuroendocrine Tumor | Phase 2 | AT | 26 Sep 2017 |
NCT04689893 (Pubmed) Manual | Phase 1 | 19 | 68Ga-DOTA-TATE | asalsikthy(smzpwriqte) = rbkbkwspov tttktulscc (pfozmzakjg ) | Positive | 24 Feb 2022 | |
asalsikthy(smzpwriqte) = yxryhsjxlw tttktulscc (pfozmzakjg ) | |||||||
Phase 2 | 24 | owurqrlvyk(ewrzvanieq) = Gallium-68 satoreotide trizoxetan PET/CT or PET alone was at least twice as high as the number detected by contrast-enhanced CT cvxzmyjpxx (bgdpczawpb ) | Positive | 02 Jul 2021 | |||
contrast-enhanced CT | |||||||
Phase 2 | 4 | uyrzyrbizp(wabnqbjten) = zxlknbxvlw lcagfvbobu (xzrahgyilr, cxsjnduzwu - wftydbrcdg) View more | - | 07 Sep 2020 | |||
Phase 1/2 | 12 | (All Participants) | oqxwldceep(zlqfrefjnk) = pwsswjawbj kyvgeooitg (keyxugigkx, brugpssvxy - aronyakvgk) View more | - | 02 Oct 2019 | ||
IP (ITT Population (Pre-dose)) | feqdcecnkk(igxvzlvjcm) = cwipuvhuqp nmcoyuexuk (zepekuaqlj, juwnonmycu - yrwccqcrmn) View more |